Phenytoin in rheumatoid arthritis.
In a prospective open study, 18 patients with active rheumatoid arthritis were treated with phenytoin (300 mg/day) for 32 weeks. Clinical assessments improved significantly and there was no relapse 8 weeks after drug withdrawal. Serum C-reactive protein, plasma viscosity and hemoglobin also improved but changes were not significant. Serum phenytoin concentrations were lower than anticipated. Side effects were mild and caused 2 patients to withdraw. Our observations and the known effects of phenytoin on the immune system and collagen metabolism suggest that further controlled studies using higher doses are warranted.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001809:Blood Viscosity; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies
D000893:Anti-Inflammatory Agents; D006454:Hemoglobins; D010672:Phenytoin; D002097:C-Reactive Protein